Introduction
death, IDA
ADVERSE EFFECTS, IRON DEFICIENCY ANEMIA
Iron deficiency anemia (IDA) remains a major problem in chronic hemodialysis patientsThe PIVOTAL trialOur aim was to find appropriate doses of maintenance iron therapy. Therefore, we conducted a randomized controlled trial to compare the efficacy of 100 mg IV iron with 200 mg IV iron per month regimens to minimize monthly ESA doses. We also explored the incidence of death, absolute IDA, blood transfusion, quality of life, changes in hemoglobin (Hb), ferritin levels, TSAT, and other adverse effects.